Molly Curran

Vice President Operations at Generian

Molly Curran has a diverse work experience spanning different industries. Molly began their career at Fletcher Spaght Inc / Fletcher Spaght Ventures as an Associate Consultant from January 2007 to February 2010. Molly then joined Trinity Partners as a Consultant, specializing in Primary Market Research from March 2010 to August 2011. Following that, Molly worked at ZOLL Medical Corporation as a Product Manager, specifically focusing on New Product Planning from August 2011 to January 2014. Molly then transitioned to UPMC Enterprises as a Program Manager, where they worked from January 2014 to February 2020. In 2019, Molly took on the role of Senior Director of Operations at Generian, a position they currently hold. Additionally, in October 2019, they participated in the Leadership Pittsburgh Inc.'s LDI Class XXVII, which concluded in May 2020.

Molly Curran holds a Bachelor of Science with Honors degree in Materials Engineering from Brown University and a Masters of Engineering Management (MEM) degree from Dartmouth College. The MEM program was a collaborative program taught by the Thayer School of Engineering and the Tuck School of Business. In addition to their formal education, Molly Curran has obtained additional certifications including a Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation from Tufts CSDD in April 2022, and a PMC-II certification from Pragmatic Marketing in July 2014.

Location

Pittsburgh, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


Generian

Generian team has developed an innovative approach to uncover first-in-class, gain-of-function drugs that activate key cellular networks linked to quality control and metabolism. Activation of these validated networks represents a unique approach with applicability across a broad range of chronic diseases. Led by top researchers in the fields ofaging, small molecule drug development, and E3 ubiquitin ligase biology, Generian's platform will transform how we treat a wide array of both rare and common conditions using small molecules to reset and restore cellular homeostasis.


Employees

1-10

Links